Abstract
Histone deacetylases (HDACs) and Histone acetyltransferases (HATs) are two kinds of enzymes, which can, by reversible deacetylation and acetylation, modify the structure and function of chromatin histones that are involved in the regulation of gene expression, as well as many non-histone proteins that regulate cell function in eukaryotes. Compared with HATs, HDACs have attracted more and more attentions for two main reasons over the past few years. First, the relationship of HDACs and cancer, as well as several other diseases has been confirmed. Second, many HDAC inhibitors (HDACi) have entered pre-clinical or clinical research as anti-cancer agents and shown satisfying effects. HDACs, including 18 members at least, are subdivided into 4 classes that generally have high structure similarity and related substrate specificity within classes, but have divergent sequence and different functions even between within classes. This review will introduce the relationship between HDACs and cancer along with the enzymes structure and main function.
Keywords: Histone deacetylases, Structure, Function, HDAC inhibitors, Anti-cancer agents
Current Medicinal Chemistry
Title: The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Volume: 15 Issue: 27
Author(s): Yingjie Zhang, Hao Fang, Jie Jiao and Wenfang Xu
Affiliation:
Keywords: Histone deacetylases, Structure, Function, HDAC inhibitors, Anti-cancer agents
Abstract: Histone deacetylases (HDACs) and Histone acetyltransferases (HATs) are two kinds of enzymes, which can, by reversible deacetylation and acetylation, modify the structure and function of chromatin histones that are involved in the regulation of gene expression, as well as many non-histone proteins that regulate cell function in eukaryotes. Compared with HATs, HDACs have attracted more and more attentions for two main reasons over the past few years. First, the relationship of HDACs and cancer, as well as several other diseases has been confirmed. Second, many HDAC inhibitors (HDACi) have entered pre-clinical or clinical research as anti-cancer agents and shown satisfying effects. HDACs, including 18 members at least, are subdivided into 4 classes that generally have high structure similarity and related substrate specificity within classes, but have divergent sequence and different functions even between within classes. This review will introduce the relationship between HDACs and cancer along with the enzymes structure and main function.
Export Options
About this article
Cite this article as:
Zhang Yingjie, Fang Hao, Jiao Jie and Xu Wenfang, The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy, Current Medicinal Chemistry 2008; 15 (27) . https://dx.doi.org/10.2174/092986708786242796
DOI https://dx.doi.org/10.2174/092986708786242796 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
Current Pharmaceutical Biotechnology The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry Pgp and FLT3: Identification and Modulation of Two Proteins that Lead to Chemotherapy Resistance in Acute Myeloid Leukemia
Current Medicinal Chemistry Innate Immunity and the Heart
Current Pharmaceutical Design Subject Index To Volume 13
Current Medicinal Chemistry miRNAs in Bone Development
Current Genomics Chemical and Potential Biological Perspectives of Genus Sarcococca (Buxaceae)
The Natural Products Journal Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics